An observational study in Multiple Sclerosis, sponsored by Centre Hospitalier Universitaire de Nīmes. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes — 1 open to participants now, 3 under way, none of them phase 3. Multiple Sclerosis · Centre Hospitalier Universitaire de Nīmes.
Among the 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes, this one is one of 3 that started in 2019, is one of 7 observational ones, and was the 9th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →1 of the 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes is open now, in 1 country. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+ · Women only
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 81 across the 6 interventional studies, 200 across the 7 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 87 are open to participants now.
2 of the studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04860947Centre Hospitalier Universitaire de NīmesAssessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients | 2027-03 |
| NCT03981003Centre Hospitalier Universitaire de NīmesSerum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators hypothesize that serum neurofilament-light chain (NfL) levels at baseline and decrease of the macular ganglion cell complex (GCC) thickness at one year vs. baseline are as good as progression of whole brain atrophy at one year vs. baseline to predict later evolution of neurological disability in multiple sclerosis patients.
The study population is composed of consecutive adult patients, of both sexes, recruited during consultations for a CIS, RRMS or progressive MS at the Neurology department of Nîmes University Hospital (CHU). The patients recruited will have an EDSS score comprised between 0 - 7.0.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The patient has experienced a CIS, has currently a RRMS or progressive MS with:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: Brain MRI · Diagnostic Test: Spinal Cord MRI · Diagnostic Test: Retinal imaging
* Axial DWI with ADC card * Axial 2D TSE T2/DP or 3DT2 * Gadolinium injection (0.1 mmol/kg) * 3D Fluid-attenuated inversion recovery * 3D T1 with Gadolinium injection.
Sagittal T2 Sagittal T1 with Gadolinium injection
spectral-domain high definition optical coherence tomography
Change in serum Neurofilament Light Chain serum levels since baseline
pg/mL; measured by digital ELISA
Time frame: Baseline; 1 year
Change in serum Glial Fibrillary Acidic Protein (GFAP) serum levels since baseline
pg/mL; measured by digital ELISA
Time frame: Baseline; 1 year
Change in Ganglion Cell Complex thickness since baseline
Measured by Optical Coherence Tomography
Time frame: Baseline; 1 year
Change in whole brain volume since baseline
Assessed by MRI
Time frame: Baseline; 1 year
Expanded Disability Status Scale
Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)
Time frame: Baseline
Expanded Disability Status Scale
Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)
Time frame: 3 years
Whole brain volume
assessed by MRI
Time frame: Inclusion
Whole brain volume
assessed by MRI
Time frame: 6 Months
Whole brain volume
assessed by MRI
Time frame: 1 Year
Whole brain volume
assessed by MRI
Time frame: 2 years
Whole brain volume
assessed by MRI
Time frame: 3 Years
Whole brain volume
assessed by MRI
Time frame: 4 Years
Whole brain volume
assessed by MRI
Time frame: 5 years
Whole brain volume
assessed by MRI
Time frame: any relapse (max 5 years)
Expanded Disability Status Scale
Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)
Time frame: Inclusion
Expanded Disability Status Scale
Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)
Time frame: 6 Months
Expanded Disability Status Scale
Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)
Time frame: 1 year
Expanded Disability Status Scale
Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)
Time frame: 18 months
Expanded Disability Status Scale
Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)
Time frame: 2 years
Expanded Disability Status Scale
Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)
Time frame: 2.5 years
Expanded Disability Status Scale
Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)
Time frame: 3 years
Expanded Disability Status Scale
Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)
Time frame: 3.5 years
Expanded Disability Status Scale
Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)
Time frame: 4 years
Expanded Disability Status Scale
Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)
Time frame: 4.5 years
Expanded Disability Status Scale
Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)
Time frame: 5 years
Expanded Disability Status Scale
Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)
Time frame: Any relapse (Maximum 5 years)
Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness
assessed by Optical Coherence Tomography
Time frame: Inclusion
Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness
assessed by Optical Coherence Tomography
Time frame: 6 Months
Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness
assessed by Optical Coherence Tomography
Time frame: 1 Year
Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness
assessed by Optical Coherence Tomography
Time frame: 18 Months
Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness
assessed by Optical Coherence Tomography
Time frame: 2 years
Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness
assessed by Optical Coherence Tomography
Time frame: 3 Years
Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness
assessed by Optical Coherence Tomography
Time frame: 4 Years
Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness
assessed by Optical Coherence Tomography
Time frame: 5 Years
Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness
assessed by Optical Coherence Tomography
Time frame: Any relapse (maximum 5 Years)
Gadolinium-enhanced lesions
assessed by MRI
Time frame: Inclusion
Gadolinium-enhanced lesions
assessed by MRI
Time frame: 6 Months
Gadolinium-enhanced lesions
assessed by MRI
Time frame: 1 Year
Gadolinium-enhanced lesions
assessed by MRI
Time frame: 2 years
Gadolinium-enhanced lesions
assessed by MRI
Time frame: 3 Years
Gadolinium-enhanced lesions
assessed by MRI
Time frame: 4 Years
Gadolinium-enhanced lesions
assessed by MRI
Time frame: 5 Years
Gadolinium-enhanced lesions
assessed by MRI
Time frame: Any relapse (Maximum 5 Years)
T2 lesion volume,
assessed by MRI
Time frame: Inclusion
T2 lesion volume,
assessed by MRI
Time frame: 6 Months
T2 lesion volume,
assessed by MRI
Time frame: 1 Year
T2 lesion volume,
assessed by MRI
Time frame: 2 years
T2 lesion volume,
assessed by MRI
Time frame: 3 Years
T2 lesion volume,
assessed by MRI
Time frame: 4 Years
T2 lesion volume,
assessed by MRI
Time frame: 5 years
T2 lesion volume,
assessed by MRI
Time frame: Any relapse (maximum 5 years)
Grey matter atrophy
assessed by MRI
Time frame: Inclusion
Grey matter atrophy
assessed by MRI
Time frame: 6 Months
Grey matter atrophy
assessed by MRI
Time frame: 1 Year
Grey matter atrophy
assessed by MRI
Time frame: 2 years
Grey matter atrophy
assessed by MRI
Time frame: 3 Years
Grey matter atrophy
assessed by MRI
Time frame: 4 Years
Grey matter atrophy
assessed by MRI
Time frame: 5 Years
Grey matter atrophy
assessed by MRI
Time frame: Any relapse (maximum 5 Years)
White matter atrophy
assessed by MRI
Time frame: Inclusion
White matter atrophy
assessed by MRI
Time frame: 6 Months
White matter atrophy
assessed by MRI
Time frame: 1 Year
White matter atrophy
assessed by MRI
Time frame: 2 years
White matter atrophy
assessed by MRI
Time frame: 3 Years
White matter atrophy
assessed by MRI
Time frame: 4 Years
White matter atrophy
assessed by MRI
Time frame: 5 years
White matter atrophy
assessed by MRI
Time frame: Any relapse (maximum 5 years)
Thalamic atrophy
assessed by MRI
Time frame: Inclusion
Thalamic atrophy
assessed by MRI
Time frame: 6 Months
Thalamic atrophy
assessed by MRI
Time frame: 1 Year
Thalamic atrophy
assessed by MRI
Time frame: 2 years
Thalamic atrophy
assessed by MRI
Time frame: 3 Years
Thalamic atrophy
assessed by MRI
Time frame: 4 Years
Thalamic atrophy
assessed by MRI
Time frame: 5 years
Thalamic atrophy
assessed by MRI
Time frame: Any relapse (maximum 5 years)
Disease modifying drugs classification
Drug class (1st, 2nd or 3rd line)
Time frame: Inclusion
Disease modifying drugs classification
Drug class (1st, 2nd or 3rd line)
Time frame: until end of study (5 years)
serum NfL levels
pg/mL; measured by digital ELISA
Time frame: 6 Months
serum GFAP levels
pg/mL; measured by digital ELISA
Time frame: 6 Months
serum NfL levels
pg/mL; measured by digital ELISA
Time frame: 2 years
serum GFAP levels
pg/mL; measured by digital ELISA
Time frame: 2 years
serum NfL levels
pg/mL; measured by digital ELISA
Time frame: 3 years
serum GFAP levels
pg/mL; measured by digital ELISA
Time frame: 3 years
serum NfL levels
pg/mL; measured by digital ELISA
Time frame: 4 years
serum GFAP levels
pg/mL; measured by digital ELISA
Time frame: 4 years
serum NfL levels
pg/mL; measured by digital ELISA
Time frame: 5 years
serum GFAP levels
pg/mL; measured by digital ELISA
Time frame: 5 years
serum NfL levels
pg/mL; measured by digital ELISA
Time frame: Any relapse (maximum 5 years)
serum GFAP levels
pg/mL; measured by digital ELISA
Time frame: Any relapse (maximum 5 years)
Multiple Sclerosis Functional Composite
21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)
Time frame: Inclusion
Multiple Sclerosis Functional Composite
21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)
Time frame: 6 Months
Multiple Sclerosis Functional Composite
21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)
Time frame: 1 Year
Multiple Sclerosis Functional Composite
21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)
Time frame: 2 years
Multiple Sclerosis Functional Composite
21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)
Time frame: 3 years
Multiple Sclerosis Functional Composite
21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)
Time frame: 4 years
Multiple Sclerosis Functional Composite
21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)
Time frame: 5 years
Multiple Sclerosis Functional Composite
21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)
Time frame: Any relapse (maximum 5 years)
Time to walk 100 meters
Seconds
Time frame: Inclusion
Time to walk 100 meters
Seconds
Time frame: 6 Months
Time to walk 100 meters
Seconds
Time frame: 1 Year
Time to walk 100 meters
Seconds
Time frame: 2 years
Time to walk 100 meters
Seconds
Time frame: 3 years
Time to walk 100 meters
Seconds
Time frame: 4 years
Time to walk 100 meters
Seconds
Time frame: 5 years
Time to walk 100 meters
Seconds
Time frame: Any relapse (maximum 5 years)
2 Minute walking distance
Meters
Time frame: Inclusion
2 Minute walking distance
Meters
Time frame: 6 Months
2 Minute walking distance
Meters
Time frame: 1 Year
2 Minute walking distance
Meters
Time frame: 2 years
2 Minute walking distance
Meters
Time frame: 3 years
2 Minute walking distance
Meters
Time frame: 4 years
2 Minute walking distance
Meters
Time frame: 5 years
2 Minute walking distance
Meters
Time frame: Any relapse (maximum 5 years)
Cognitive Impairment
Symbol Digit Modalities Test
Time frame: Inclusion
Cognitive Impairment
Symbol Digit Modalities Test
Time frame: 6 months
Cognitive Impairment
Symbol Digit Modalities Test
Time frame: 1 Year
Cognitive Impairment
Symbol Digit Modalities Test
Time frame: 2 years
Cognitive Impairment
Symbol Digit Modalities Test
Time frame: 3 years
Cognitive Impairment
Symbol Digit Modalities Test
Time frame: 4 years
Cognitive Impairment
Symbol Digit Modalities Test
Time frame: 5 years
Cognitive Impairment
Symbol Digit Modalities Test
Time frame: Any relapse (maximum 5 years)
Cognitive evaluation
Brief International Cognitive Assessment for Multiple Sclerosis
Time frame: Inclusion
Cognitive evaluation
Brief International Cognitive Assessment for Multiple Sclerosis
Time frame: 6 Months
Cognitive evaluation
Brief International Cognitive Assessment for Multiple Sclerosis
Time frame: 1 Year
Cognitive evaluation
Brief International Cognitive Assessment for Multiple Sclerosis
Time frame: 2 years
Cognitive evaluation
Brief International Cognitive Assessment for Multiple Sclerosis
Time frame: 3 years
Cognitive evaluation
Brief International Cognitive Assessment for Multiple Sclerosis
Time frame: 4 years
Cognitive evaluation
Brief International Cognitive Assessment for Multiple Sclerosis
Time frame: 5 years
Cognitive evaluation
Brief International Cognitive Assessment for Multiple Sclerosis
Time frame: Any relapse (maximum 5 years)
Health-related quality of life
EQ-5D-5L
Time frame: Inclusion
Health-related quality of life
EQ-5D-5L
Time frame: 6 Months
Health-related quality of life
EQ-5D-5L
Time frame: 1 Year
Health-related quality of life
EQ-5D-5L
Time frame: 2 years
Health-related quality of life
EQ-5D-5L
Time frame: 3 years
Health-related quality of life
EQ-5D-5L
Time frame: 4 years
Health-related quality of life
EQ-5D-5L
Time frame: 5 years
Health-related quality of life
EQ-5D-5L
Time frame: Any relapse (maximum 5 years)
Impact of MS on daily life
Multiple Sclerosis Impact Scale (MSIS-29)
Time frame: Inclusion
Impact of MS on daily life
Multiple Sclerosis Impact Scale (MSIS-29)
Time frame: 6 Months
Impact of MS on daily life
Multiple Sclerosis Impact Scale (MSIS-29)
Time frame: 1 Year
Impact of MS on daily life
Multiple Sclerosis Impact Scale (MSIS-29)
Time frame: 2 years
Impact of MS on daily life
Multiple Sclerosis Impact Scale (MSIS-29)
Time frame: 3 years
Impact of MS on daily life
Multiple Sclerosis Impact Scale (MSIS-29)
Time frame: 4 years
Impact of MS on daily life
Multiple Sclerosis Impact Scale (MSIS-29)
Time frame: 5 years
Impact of MS on daily life
Multiple Sclerosis Impact Scale (MSIS-29)
Time frame: Any relapse (maximum 5 years)
Fatigue
Modified Fatigue Impact Scale
Time frame: Inclusion
Fatigue
Modified Fatigue Impact Scale
Time frame: 6 Months
Fatigue
Modified Fatigue Impact Scale
Time frame: 1 Year
Fatigue
Modified Fatigue Impact Scale
Time frame: 2 years
Fatigue
Modified Fatigue Impact Scale
Time frame: 3 years
Fatigue
Modified Fatigue Impact Scale
Time frame: 4 years
Fatigue
Modified Fatigue Impact Scale
Time frame: 5 years
Fatigue
Modified Fatigue Impact Scale
Time frame: Any relapse (maximum 5 years)
Visual acuity
0= low, 10= good
Time frame: Inclusion
Visual acuity
0= low, 10= good
Time frame: 6 Months
Visual acuity
0= low, 10= good
Time frame: 1 Year
Visual acuity
0= low, 10= good
Time frame: 2 years
Visual acuity
0= low, 10= good
Time frame: 3 years
Visual acuity
0= low, 10= good
Time frame: 4 years
Visual acuity
0= low, 10= good
Time frame: 5 years
Visual acuity
0= low, 10 good
Time frame: Any relapse (maximum 5 years)
Low contrast visual acuity
0= low, 10 good
Time frame: Inclusion
Low contrast visual acuity
0= low, 10 good
Time frame: 6 Months
Low contrast visual acuity
0= low, 10 good
Time frame: 1 Year
Low contrast visual acuity
0= low, 10 good
Time frame: 2 years
Low contrast visual acuity
0= low, 10 good
Time frame: 3 years,
Low contrast visual acuity
0= low, 10 good
Time frame: 4 years
Low contrast visual acuity
0= low, 10 good
Time frame: 5 years
Low contrast visual acuity
0= low, 10 good
Time frame: Any relapse (maximum 5 years)
Relapse description
monofocal, plurifocal
Time frame: At relapse (maximum 5 years)
Number of new lesions
Measured by MRI
Time frame: At relapse (maximum 5 years)
Started Jun 2019 (actual). Primary completion is estimated for Mar 2027, 93 months after the start.
Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 93 months is above that.
Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Jun 2026 → Mar 2027 and completion Jun 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nīmes →